VSEE HEALTH, INC.
No SEC Form 4 filings for $VSEE in the last 30 days.
See all $VSEE insider activity →VSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into Material Definitive Agreement. Strata Agreement On September 2, 2026, VSee Health, Inc., a Delaware corporation (the “Company”), executed a Strata Purchase Agreement (the “Strata Agreement”) with Clearthink Capital Partners, LLC (“Clearthink”). Pursuant to th
VSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On August 27, 2026, Scott Metzger resigned, effective immediately, as a member of the Board of Directors (the “Board”) of VSe
VSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 25, 2026, VSee Health, Inc., a Delaware Corporation (the “Company”), held its annual meeting of stockholders for its fiscal year ended December 31, 2026 (the “Annual Meeting”). As of July 6, 2026, the record
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VSEE (VSEE HEALTH, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent VSEE coverage spans corporate actions, mergers & acquisitions and financial news.
Potential infusion of up to $5 M for working capital; dilution limited to <10% ownership.
Board resignation may affect governance perception but no immediate financial impact.
The meeting confirms board members and authorizes a potential reverse split, which could affect share count and price perception.
The LOI signals a potential step-change in VSee’s revenue mix toward commerce and transaction fees, but execution risk remains until definitive agreements and approvals.
The filing discloses a new convertible debt financing, which can dilute equity on conversion and signals near-term funding needs.
AlphAI scores every news story that mentions VSEE with an AI model for sentiment and relevance, and aggregates insider trades from VSEE HEALTH, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
VSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into Material Definitive Agreement. Strata Agreement On September 2, 2026, VSee Health, Inc., a Delaware corporation (the “Company”), executed a Strata Purchase Agreement (the “Strata Agreement”) with Clearthink Capital Partners, LLC (“Clearthink”). Pursuant to th
1 min readVSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On August 27, 2026, Scott Metzger resigned, effective immediately, as a member of the Board of Directors (the “Board”) of VSe
1 min readVSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 25, 2026, VSee Health, Inc., a Delaware Corporation (the “Company”), held its annual meeting of stockholders for its fiscal year ended December 31, 2026 (the “Annual Meeting”). As of July 6, 2026, the record
1 min readVSee Health, Inc. signed a non-binding LOI to acquire healthcare technology and operating assets valued at about $42 million. The target supports a clinic-based wellness commerce platform with an unaudited annual revenue run rate over $35 million and about $7 million in EBITDA. VSee says it would integrate ordering and payment workflows into its API virtual care platform, subject to due diligence and approvals.
4 min readVSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Labrys Convertible Promissory Note Financing On June 30, 2026, VSee Health, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Labrys SPA”) with an institutional investor (“Labrys”
4 min readVSee Health (NASDAQ:VSEE) said it entered a non-binding letter of intent to acquire certain healthcare technology and operating assets for $42 million. The target assets have an unaudited run rate above $35 million in annualized revenue and about $7 million in EBITDA. VSee will conduct due diligence and negotiate definitive terms; no deal is assured.
4 min readVSee Health (NASDAQ:VSEE) said its board has initiated a comprehensive strategic review to pursue alternatives such as partnerships, mergers, acquisitions, licensing, and capital formation. The company is in late-stage discussions with potential strategic partners, aiming to accelerate growth and maximize long-term shareholder value. No transaction is assured.
2 min readVSEE HEALTH, INC. (VSEE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001864531 0001864531 2026-07-21 2026-07-21 0001864531 VSEE:CommonStock0.0001ParValuePerShareMember 2026-07-21 2026-07-21 0001864531 VSEE:WarrantsWhichEntitlesHolderToPurchaseOne1ShareOfCommonStockAtPriceOf11.50PerWholeShareMember 2026-07-21 2026-07-21 iso4217:USD xbrli:sha
4 min readVSee Health, Inc. (NASDAQ:VSEE) said its board approved a proposed reverse stock split of up to 80-for-1, subject to regulatory and shareholder approvals, to support Nasdaq listing. The company terminated a previously announced standby equity purchase agreement and said it has no active equity financing facility expected to cause near-term dilution. As of July 6, 2026, it had 55,679,813 shares outstanding.
3 min readVSee Health (NASDAQ:VSEE) issued a shareholder update from CEO Dr. Imoigele Aisiku. The company says it has shifted resources to its iDoc TeleHealth solutions after divesting lab operations, expanding hospital adoption from 3 to 58. Management expects iDoc to reach profitability within 12 months, citing lower costs and improved operating leverage.
2 min read
